Efficacy and Safety of Topical @entity2993 for the Treatment of Dry Eye Associated with XXXX : A Pilot Study.

@entity1 @entity14985 @entity2993 @entity936 @entity941
AIMS: To elucidate if topically applied @entity2993 safely decreases corneal @entity941 staining in dry eyes associated with @entity14985 . METHODS: Ten @entity936 and @entity14985 (DEB) @entity1 were enroled in a prospective pilot study. All @entity1 were treated with topical @entity2993 (50  M) 8 times a day for 4 weeks and allowed to continue with their existing @entity936 treatment. The @entity1 were examined weekly for 4 weeks. The primary outcome measure was corneal @entity941 staining. Secondary outcome measures were tear film break-up time (BUT), Schirmer I testing, @entity14985 score and bulbar conjunctival injection. The subjective efficacy was evaluated with global symptom and facial analogue scores. RESULTS: An improvement in corneal @entity941 staining in the treated eye by >1 point from baseline to completion of the trial at week 4 was found in 9 of 10 @entity1 (p < 0.01). Topical @entity2993 significantly improved the tear film BUT (p < 0.01), @entity14985 score (p < 0.05) and bulbar conjunctival injection (p < 0.05). The global symptom score and facial analogue score also improved (p < 0.05). There were no side effects. CONCLUSION: Topical @entity2993 is a potential therapy for DEB @entity1 . Larger comparative clinical studies are required to establish the efficacy and safety of topical @entity2993 .    2015 S. Karger AG, Basel.
